https://www.noah.bio/insight/e83ce30c-4faf-4b28-b23a-da4655045429
VYLOY (Zolbetuximab-clzb) in First-Line HER2-Negative, CLDN18.2-Positive Gastric and...
Zolbetuximab establishes a targeted first-line treatment option for HER2-negative, CLDN18.2-positive gastric/GEJ adenocarcinoma, supported by pivotal efficacy...